Selected article for: "decreased lymphocyte and lymphocyte decrease"

Author: Buonaguro, Franco Maria; Puzanov, Igor; Ascierto, Paolo Antonio
Title: Anti-IL6R role in treatment of COVID-19-related ARDS
  • Document date: 2020_4_14
  • ID: 0pigqtzt_6
    Snippet: In this single arm study, patients with moderate to severe COVID-19 disease received one or two doses of tocilizumab (400 mg/dose) in addition to standard therapies used including lopinavir and methylprednisolone as reported in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th interim edition) [2] . Most patients experienced clinical improvement including lower oxygen requirement (15/21, 75%), decrease of CRP, increase in .....
    Document: In this single arm study, patients with moderate to severe COVID-19 disease received one or two doses of tocilizumab (400 mg/dose) in addition to standard therapies used including lopinavir and methylprednisolone as reported in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th interim edition) [2] . Most patients experienced clinical improvement including lower oxygen requirement (15/21, 75%), decrease of CRP, increase in lymphocyte levels, decreased fever and improved chest tightness. Two patients were taken off the ventilator within 5 days after the treatment with tocilizumab, another one improved significantly [1] .

    Search related documents:
    Co phrase search for related documents